$9.00 Million in Sales Expected for MaxCyte, Inc. (NASDAQ:MXCT) This Quarter

Analysts expect MaxCyte, Inc. (NASDAQ:MXCT – Get Rating) to post sales of $9.00 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for MaxCyte’s earnings, with estimates ranging from $8.90 million to $9.10 million. MaxCyte reported sales of $7.11 million in the same quarter last year, which would suggest […]

Related Keywords

,Maxcyte Inc ,Grandeur Peak Global Advisors ,Zacks Investment Research ,Ensign Peak Advisors Inc ,Metlife Investment Management ,Nasdaq ,Maxcyte Company Profile Get Rating ,Proshare Advisors ,Get Rating ,Investment Research ,Life Investment Management ,Street Group ,Share Advisors ,Peak Advisors Inc ,Peak Global Advisors ,Cyte Company Profile ,Maxcyte ,Nasdaq Mxct ,Mxct ,Medical ,Ratings ,Consensus ,